CN115998726A - Application of coltsfoot ketone in preparing medicament for preventing and treating liver steatosis or fatty liver - Google Patents
Application of coltsfoot ketone in preparing medicament for preventing and treating liver steatosis or fatty liver Download PDFInfo
- Publication number
- CN115998726A CN115998726A CN202310044103.7A CN202310044103A CN115998726A CN 115998726 A CN115998726 A CN 115998726A CN 202310044103 A CN202310044103 A CN 202310044103A CN 115998726 A CN115998726 A CN 115998726A
- Authority
- CN
- China
- Prior art keywords
- tus
- coltsfoot
- fatty liver
- ketone
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 56
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 56
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 42
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 235000004869 Tussilago farfara Nutrition 0.000 title claims abstract description 33
- 150000002576 ketones Chemical class 0.000 title claims abstract description 32
- 240000000377 Tussilago farfara Species 0.000 title 1
- 241000249864 Tussilago Species 0.000 claims abstract description 32
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 36
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 33
- 235000009200 high fat diet Nutrition 0.000 abstract description 16
- 238000002474 experimental method Methods 0.000 abstract description 10
- 238000001727 in vivo Methods 0.000 abstract description 9
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 231100000053 low toxicity Toxicity 0.000 abstract description 3
- 230000035508 accumulation Effects 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000000678 effect on lipid Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 72
- 241000699670 Mus sp. Species 0.000 description 37
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 33
- 239000003925 fat Substances 0.000 description 32
- 150000002632 lipids Chemical class 0.000 description 26
- 201000007270 liver cancer Diseases 0.000 description 21
- 208000014018 liver neoplasm Diseases 0.000 description 21
- 210000004185 liver Anatomy 0.000 description 20
- 230000037149 energy metabolism Effects 0.000 description 18
- 230000001603 reducing effect Effects 0.000 description 18
- 230000008021 deposition Effects 0.000 description 15
- 210000003470 mitochondria Anatomy 0.000 description 15
- 206010022489 Insulin Resistance Diseases 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 230000007850 degeneration Effects 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000006372 lipid accumulation Effects 0.000 description 5
- 230000037356 lipid metabolism Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000013382 DNA quantification Methods 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000081 effect on glucose Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 235000021069 high fat-high sugar diet Nutrition 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000009223 neuronal apoptosis Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- -1 oxygen free radical Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 229940126589 solid medicine Drugs 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses application of coltsfoot ketone in preparing a medicine for preventing and treating hepatic steatosis or fatty liver, and belongs to the technical field of medicines. From the aspects of cell experiments and in-vivo experiments, the embodiment of the invention proves that coltsfoot ketone can improve liver steatosis and has prevention and treatment effects on fatty liver, and the coltsfoot ketone can be applied to preparing medicaments for preventing and treating liver steatosis or fatty liver. Meanwhile, coltsfoot ketone is taken as a natural low-toxicity small molecular compound, has obvious relieving effect on lipid accumulation induced by high-fat diet, plays an important role in the treatment of non-alcoholic fatty liver disease, and has wide application prospect.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to application of coltsfoot ketone in preparation of a medicine for preventing and treating hepatic steatosis or fatty liver.
Background
Coltsfoot ketone (TUS) is a sesquiterpene component isolated from flos Farfarae. Early studies showed that TUS has a variety of pharmacological activities. TUS has the partial effects of relieving cough and asthma and protecting the cardiovascular system. TUS can inhibit lipopolysaccharide-induced neuronal apoptosis by scavenging active oxygen. TUS inhibits the release of NO, PGE2, TNF- α, and the expression of iNOS and COX-2 by LPS stimulating BV-2 microglial cells by inhibiting NF-kB pathway, thereby inhibiting the release of inflammatory factors. And has also been found to have antiallergic and anticancer effects, etc. Coltsfoot ketone also has important function in preparing anti-aging medicines and health foods.
With the increasing living standard of people, the life style and the dietary structure are changed, the number of obese people is increased year by year, and the incidence of nonalcoholic fatty liver disease (NAFLD) is also obviously increased. NAFLD is a chronic liver disease, and excessive intake of high fat diet for a long period induces overload of free fatty acids in liver, leading to fatty degeneration of liver cells, and also causes inflammation and fibrosis of liver, and may further develop into liver cirrhosis, liver failure, and liver cancer.
NAFLD is a type of syndrome characterized by fat deposition in liver cells, which has plagued humans for many years, and a definite and effective therapeutic method has not been studied yet. Long-term high-fat high-sugar diet induces liver glycolipid metabolic disorders leading to the occurrence of NAFLD. An imbalance between lipid storage (e.g., triglycerides in lipid droplets) and fatty acid breakdown (primarily through fatty acid beta-oxidation) can lead to an increase in abnormal fat deposition, leading to metabolic syndrome. Oxidative stress, mitochondrial damage, and insulin resistance from lipid metabolism disorders are considered to be major drivers of the pathogenesis of metabolic-related fatty liver. Thus, inhibiting lipid production, inducing fatty acid breakdown, and improving oxidative stress and promoting energy expenditure would be helpful in preventing NAFLD-related diseases.
To date, there is no report in the prior art on coltsfoot ketone in the preparation of a medicament for treating non-alcoholic fatty liver disease and fatty liver degeneration, nor is there a similar suggestion or attempt.
Disclosure of Invention
The invention aims to provide application of coltsfoot ketone in preparing a medicine for preventing and treating hepatic steatosis or fatty liver, and aims to solve the problem that a low-toxicity natural small-molecule medicine for effectively preventing or treating hepatic steatosis or fatty liver is lacking at present.
The aim of the invention is realized by the following technical scheme:
the examples of the present invention show from both living and cellular assays:
TUS has no obvious effect on the activity of HepG2 human liver cancer cell at 120 mu M.
TUS can relieve lipid disorders in human hepatoma cells HepG2 by reducing TG levels in the human hepatoma cells HepG2 and intracellular lipid droplets; TUS can promote the energy metabolism of the human hepatoma cell HepG2 by increasing the number of mitochondria of the human hepatoma cell HepG2 and the DNA level and ATP level of the mitochondria; in addition, TUS exerts an antioxidant effect by reducing the ROS and MDA levels and increasing the levels of antioxidants SOD, CAT and GSH in the human hepatoma cell HepG 2.
In addition, TUS is effective in reducing weight gain in mice caused by a high-fat diet, reducing fat percentage gain, and reducing fat distribution caused by a high-fat diet. And TUS can improve glucose tolerance and insulin sensitivity of the mice, TUS can enhance energy metabolism level of the mice; meanwhile, TUS is found to reduce the TG level of liver, reduce liver lipid deposition and obviously relieve lipid accumulation induced by high-fat diet, and has the effects of improving liver steatosis and preventing and treating fatty liver.
According to the results of in vivo and cell tests in the embodiment of the invention, coltsfoot ketone is applied to preparation of medicines for preventing and treating hepatic steatosis or fatty liver.
As a preferred embodiment, the control includes prevention, alleviation, treatment.
In a preferred embodiment, the fatty liver is a non-alcoholic fatty liver.
As a preferred embodiment, the preparation of the medicine for preventing and treating liver steatosis or fatty liver is carried out, and the prepared medicine is an oral preparation medicine.
The oral preparation medicine is one of capsule preparation, soft capsule preparation, oral liquid preparation, dripping pill preparation or tablet preparation medicine.
The oral preparation also contains pharmaceutically acceptable auxiliary materials and/or carriers.
In a preferred embodiment, the coltsfoot ketone is used in an amount of 15mg/kg to 30mg/kg; preferably 15mg/kg and 30mg/kg.
Compared with the prior art, the invention has the following beneficial effects:
in the embodiment of the invention, it is confirmed that TUS can relieve lipid disorders in the human hepatoma cell HepG2 by reducing the TG level in the human hepatoma cell HepG2 and reducing intracellular lipid drops on the cell test level; TUS can increase the quantity of human liver cancer cell HepG2 mitochondria, and the DNA level and ATP level of mitochondria, and can promote the energy metabolism of human liver cancer cell HepG 2; in addition, TUS exerts an antioxidant effect by reducing the ROS and MDA levels and increasing the levels of antioxidants SOD, CAT and GSH in the human hepatoma cell HepG 2.
In the aspect of in vivo experiments, TUS can effectively reduce the body weight increase caused by high-fat diet, can effectively degrade the fat percentage increase, and can reduce the fat distribution caused by high-fat diet. And TUS can improve glucose tolerance and insulin sensitivity of the mice, TUS can improve energy metabolism level of the mice; meanwhile, TUS is found to reduce the TG level of liver and liver lipid deposition, and has the effects of improving liver steatosis and preventing and treating fatty liver. And it is verified that TUS has no obvious effect on the activity of human hepatoma cells at 120. Mu.M. Therefore, the TUS can be applied to the preparation of the medicine for preventing and treating liver steatosis or fatty liver, and the medicine application has no side effects such as cytotoxicity and the like. Thereby providing a natural micromolecular medicine-coltsfoot ketone for effectively preventing or treating liver steatosis or fatty liver. In addition, coltsfoot ketone is taken as a natural small molecular compound, has obvious effect of relieving lipid accumulation induced by high-fat diet, plays an important role in the treatment of non-alcoholic fatty liver disease, and has wide application prospect.
Drawings
FIG. 1 is a schematic diagram of a cell-related experiment in accordance with an embodiment of the present invention.
FIG. 2 is a schematic diagram of an in vivo study-related experiment in accordance with the first embodiment of the present invention.
FIG. 3 is a graph showing the effect of TUS at various concentrations on the activity of HepG2 human hepatoma cells.
FIG. 4 is a graph showing the results of detecting the TG concentration in HepG2 human liver cancer cells after TUS treatment at various concentrations.
FIG. 5 is a graph showing the results of oil red O staining of HepG2 human hepatoma cells after TUS treatment; wherein the left plot is of a TUS treatment of 0. Mu.M and the right plot is of a TUS treatment of 70. Mu.M.
FIG. 6 is a graph showing the results of detecting the mitochondrial number of HepG2 human hepatoma cells after TUS treatment; wherein the left plot is of a TUS treatment of 0. Mu.M and the right plot is of a TUS treatment of 70. Mu.M.
FIG. 7 is a graph showing the results of detecting mitochondrial DNA levels of HepG2 human hepatoma cells after TUS treatment.
FIG. 8 is a graph showing the results of detecting ATP levels in mitochondria of HepG2 human hepatoma cells after TUS treatment.
FIG. 9 is a graph showing the results of detecting ROS levels in HepG2 human hepatoma cells after TUS treatment.
FIG. 10 is a graph showing the results of MDA levels of HepG2 human hepatoma cells after TUS treatment.
FIG. 11 is a graph showing the results of detecting the SOD level of HepG2 human liver cancer cell after TUS treatment.
FIG. 12 is a graph showing the results of CAT levels in HepG2 human hepatoma cells after TUS treatment.
FIG. 13 is a graph showing the results of detecting GSH levels in HepG2 human hepatoma cells after TUS treatment.
FIG. 14 is a graph showing the results of weight measurement of mice after TUS treatment.
Fig. 15 is a graph showing the results of nuclear magnetic measurement of fat percentage in the mice after TUS treatment.
FIG. 16 is a graph showing the results of CT detection of fat distribution in TUS treated mice.
Fig. 17 is a graph showing the results of HE staining of epididymal adipose tissue after TUS treatment.
FIG. 18 is a graph showing the results of glucose tolerance (GTT) test performed on TUS treated mice.
FIG. 19 is a graph showing the results of insulin sensitivity (ITT) testing of TUS treated mice.
FIG. 20 is a graph showing metabolism in TUS treated miceObserving a test result graph of energy metabolism in a cage; wherein A-B is O 2 Absorption rate (VO 2); C-D is CO 2 Consumption rate (VCO 2); E-F is a respiratory quotient (RER); G-H is energy (EE).
FIG. 21 is a graph showing the results of detecting TG levels in the liver of TUS-treated mice.
FIG. 22 is a graph of results of oil red O staining of lipid deposition in the liver of TUS treated mice.
FIG. 23 is a graph of H & E staining results of lipid deposition in the liver of TUS treated mice.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and fully with reference to the accompanying drawings, in which it is evident that the embodiments described are only some, but not all embodiments of the invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Currently, there is no low toxicity natural small molecule drug that is effective in alleviating fatty liver degeneration. In order to solve the technical problems, the invention provides application of coltsfoot ketone in preparing a medicine for preventing and treating hepatic steatosis or fatty liver.
Example 1
In this example, the effects and the application prospects of coltsfoot in fatty liver degeneration and fatty liver are explored by injecting coltsfoot into the abdominal cavity of mice with lipid metabolism disorder caused by high-fat diet and adding coltsfoot into liver cancer cells of HepG2 human through living body and cell tests respectively.
The small molecules in the embodiment are solid medicines, and the purity of the small molecules in vivo and in vitro experiments is more than or equal to 99 percent. The drugs for cell experiments were dissolved in DMSO to give a stock solution of 10mM and stored at-20 ℃.
The cell experiments are shown in FIG. 1. The effect of TUS on lipid metabolism was examined in vitro using HepG2 cells. Firstly, TUS with different concentrations is added into DMEM (common growth medium) for cell culture, and when the fusion degree of HepG2 cells reaches about 80%, the toxic effect of TUS on the cells is detected by CCK 8. After detecting the nontoxic effect, the cells are subjected to high-fat induction, namely, the cells are divided into oleic acid/palmitic acid (OA/PA) induced HepG2 human liver cancer cell groups and OA/PA induced HepG2 human liver cancer cell+TUS groups. Resting culture is carried out for 6-12h by using a serum-free culture medium when the fusion degree of the HepG2 cells reaches about 80%; after that, the culture medium was changed to OA/PA (2:1) medium and cultured for 24 hours, and TUS was added to each well of the treated group. Before dosing, small molecules were thawed at 4 ℃ and at final concentration: the concentration of the mother solution is 1: the corresponding small molecule volume was added in a 1000 ratio to give a final TUS concentration of 70. Mu.M. After 24h of treatment, the cells are taken to measure the indexes of lipid metabolism, glycometabolism, energy metabolism and oxidative stress, which are close to fatty liver degeneration. Specifically, the method comprises (1) detecting the influence of TUS on the activity of HepG2 human liver cancer cell; (2) Detecting TUS to regulate and control lipid metabolism of HepG2 human liver cancer cells, measuring intracellular TG level change, and carrying out oil red O staining on the cells to observe the change condition of cell lipid accumulation; (3) Detecting the influence of TUS on the energy metabolism of HepG2 human liver cancer cells, performing fluorescent staining on the cells, and photographing to observe the change of the cell mitochondria quantity; DNA quantification of mitochondria; measuring changes in mitochondrial ATP; (4) And detecting the change of indexes of TUS on oxidation aspects such as ROS, MDA, antioxidants SOD, CAT, GSH and the like in HepG2 human liver cancer cells.
The living experiment is shown in FIG. 2, and the experimental animal is a C57BL/6 mouse; five week old male mice were maintained at 24±2 ℃ for 12 hours in light/dark cycle, and were free to obtain food and water; after 2 weeks of adaptive feeding, the mice were randomized into the following four groups (n=7). 1) Normal diet (CK, 3.8 kcal/g, fat calories 10%, protein calories 14%, carbohydrate calories 76%); 2) High fat feed (HFD, 5.5 kcal/g, 60% fat calories, 14% protein calories, 26% carbohydrate calories); 3) High fat feed + intraperitoneal injection of 15mg/kg TUS and 4) high fat feed + intraperitoneal injection of 30mg/kg TUS. The TUS dissolution mode is as follows: 10% DMSO+40% PEG300+5% Tween-80+45% sample. The experimental time period of the mice was 12 weeks. Prior to death, mice were fasted for 4 hours and anesthetized with diethyl ether to reduce pain. Mice were sacrificed at cervical breaks and tissue samples were collected for subsequent index detection associated with fatty liver degeneration. The method specifically comprises the following steps: (5) detecting the effect of TUS on fat deposition in the mouse; (6) Detecting the effect of TUS on glucose tolerance and insulin sensitivity in the mouse; (7) detecting the effect of TUS on energy metabolism in the mouse; (8) detecting the effect of TUS on liver lipid deposition in mice.
The experimental results show that:
TUS has no obvious influence on the activity of HepG2 human liver cancer cell
As shown in FIG. 3, the effects of TUS of 0, 10. Mu.M, 30. Mu.M, 50. Mu.M, 70. Mu.M, 100. Mu.M and 120. Mu.M on the activity of HepG2 human hepatoma cells were tested, respectively, and the results showed that TUS had no significant effect on the activity of HepG2 human hepatoma cells at a concentration of 120. Mu.M or less.
TUS regulates lipid metabolism in HepG2 human hepatoma cells
Fatty liver is generally accompanied by high TG levels, with a decrease in intracellular TG following TUS addition (as shown in fig. 4). Subsequent experiments were then performed with a TUS of 70. Mu.M. To further explore the effect of TUS on lipid metabolism of HepG2 human hepatoma cells, oil red O staining was performed, and FIG. 5 shows an oil red O staining chart of HepG2 human hepatoma cells, and it can be seen that lipid droplets of TUS treated group were significantly reduced. This suggests that TUS may alleviate lipid disorders in HepG2 human hepatoma cells.
TUS increases energy metabolism of HepG2 human liver cancer cell
Mitochondria are the sites of oxidative metabolism of eukaryotes, and are the sites where sugars, fats and amino acids ultimately oxidize and release energy, and ATP produced through oxidative phosphorylation is required by the body. The study of the change of the measured cell mitochondria number shows that TUS can increase the number of the mitochondria of the HepG2 human liver cancer cell (shown in figure 6); DNA quantification of mitochondria revealed that TUS increased mitochondrial DNA levels (as shown in fig. 7); and TUS can increase mitochondrial ATP levels (as shown in figure 8). TUS is shown to increase mitochondrial numbers and has some impact on energy metabolism.
TUS has antioxidant effect on HepG2 human liver cancer cells
ROS is a highly reactive radical. When oxidative stress occurs, ROS increase, resulting in varying degrees of cellular damage and destruction, primarily manifested as oxidative damage to lipids, amino acids and proteins, nucleic acids and chromosomes. Measuring changes in oxidative aspects such as cellular ROS, and finding that ROS decrease after TUS is added (as shown in FIG. 9); MDA is a metabolic product of an important oxygen free radical in the body, can better reflect the peroxidation degree of tissues, and has a reduction after TUS is added (as shown in figure 10); SOD is an antioxidant metalloenzyme present in organisms and increases after TUS is added (as shown in fig. 11); CAT is an enzyme scavenger for scavenging hydrogen peroxide in vivo, and CAT rises after TUS is added (as shown in FIG. 12); GSH acts as an antioxidant, with GSH rising after the addition of TUS (as shown in fig. 13).
TUS has effect in reducing lipid deposition in mice
The deposition of excess lipid by high fat diet resulted in metabolic disturbance of the body, and increased body weight and body fat rate, and TUS was found to have an effect of effectively reducing body weight of mice after weighing the mice (as shown in FIG. 14). Nuclear magnetic measurements of fat percentage in mice revealed that TUS was effective in reducing the increase in fat percentage (as shown in FIG. 15).
High fat was prone to cause lipid deposition in the organism and CT examination of the fat distribution in mice revealed that the fat distribution in mice in hfd+tus group was reduced compared to HFD group (as shown in fig. 16).
The mouse epididymal fat was HE stained and TUS was found to reduce lipid droplets caused by high fat (as shown in fig. 17).
TUS can increase glucose tolerance and insulin sensitivity in mice
High fat is liable to cause insulin resistance of glucose, causes body glucose metabolism disorder, and further aggravates lipid metabolism disorder. Glucose tolerance (GTT) and insulin sensitivity (ITT) assays were performed on mice, and it was found that TUS could increase glucose tolerance (as shown in fig. 18) and insulin sensitivity (as shown in fig. 19) in mice as measured by its effect on glucose metabolism in vivo.
TUS has effect in improving energy metabolism of mice
The high fat is easy to cause energy metabolism disorder, and the improvement of energy metabolism is helpful for relieving obesity caused by the high fat and reducing fat deposition of organisms. Placing mice in metabolism cages to observe the O of the mice 2 Absorption rate (VO)2)，CO 2 Consumption rate (VCO 2), respiratory quotient (RER) and energy (EE), TUS was found to increase the energy metabolism level in mice (as shown in fig. 20).
TUS has blood lipid reducing effect on mouse liver
High fat is liable to cause liver injury, thereby leading to liver degeneration, NAFLD can be formed, and liver fibrosis and even liver cancer can be seriously induced. TG detection, oil red O staining and H & E on mouse livers found that TUS reduced TG levels in the livers (as shown in figure 21) and reduced liver lipid deposition (as shown in figures 22 and 23), indicating improved steatosis.
In summary, the experimental results show that in the embodiment of the invention, the experimental results are shown from two aspects of living body and cell tests:
TUS has no obvious effect on the activity of HepG2 human liver cancer cells within 120 mu M.
TUS can relieve lipid disorders in human hepatoma cells HepG2 by reducing TG levels in the human hepatoma cells HepG2 and intracellular lipid droplets; TUS can increase the quantity of human liver cancer cell HepG2 mitochondria, and the DNA level and ATP level of mitochondria, and can enhance the energy metabolism of human liver cancer cell HepG 2; in addition, TUS exerts an antioxidant effect by reducing the ROS and MDA levels and increasing the levels of antioxidants SOD, CAT and GSH in the human hepatoma cell HepG 2.
In addition, TUS can effectively reduce the body weight increase caused by high-fat diet, can effectively reduce the fat percentage increase, and can reduce the fat distribution caused by high-fat diet. And TUS can improve glucose tolerance and insulin sensitivity of the mice, TUS can improve energy metabolism level of the mice; meanwhile, TUS is found to reduce the TG level of liver, reduce liver lipid deposition and obviously relieve lipid accumulation induced by high-fat diet, and has the effects of improving liver steatosis and preventing and treating fatty liver.
According to the results of in vivo and cell tests in the embodiment of the invention, coltsfoot ketone is applied to preparation of medicines for preventing and treating hepatic steatosis or fatty liver.
The prevention and treatment include prevention, alleviation and treatment.
The fatty liver is nonalcoholic fatty liver.
The prepared medicine for preventing and treating liver steatosis or fatty liver is an oral preparation medicine.
The oral preparation medicine is one of capsule preparation, soft capsule preparation, oral liquid preparation, dripping pill preparation or tablet preparation medicine.
The oral preparation also contains pharmaceutically acceptable auxiliary materials and/or carriers.
The dosage of coltsfoot ketone is 15mg/kg-30mg/kg; preferably 15mg/kg and 30mg/kg.
Compared with the prior art, the invention has the following beneficial effects:
in the embodiment of the invention, on the aspect of a cell test, TUS can relieve lipid disorders in the human hepatoma cell HepG2 by reducing the TG level in the human hepatoma cell HepG2 and reducing intracellular lipid drops; TUS can promote the energy metabolism of the human hepatoma cell HepG2 by increasing the number of mitochondria of the human hepatoma cell HepG2 and the DNA level and ATP level of the mitochondria; in addition, TUS exerts an antioxidant effect by reducing the ROS and MDA levels and increasing the levels of antioxidants SOD, CAT and GSH in the human hepatoma cell HepG 2. In the aspect of in vivo experiments, TUS can effectively reduce the body weight increase caused by high-fat diet, can effectively reduce the fat percentage increase, and can reduce the fat distribution caused by high-fat diet. And TUS can improve glucose tolerance and insulin sensitivity of the mice, TUS can improve energy metabolism level of the mice; meanwhile, TUS is found to reduce the TG level of liver and liver lipid deposition, and has the effects of improving liver steatosis and preventing and treating fatty liver. And it is verified that TUS has no obvious effect on the activity of human hepatoma cells at 120. Mu.M. Therefore, the TUS can be applied to the preparation of the medicine for preventing and treating liver steatosis or fatty liver, and the medicine application has no side effects such as cytotoxicity and the like. Thereby providing a nontoxic natural micromolecular medicine-coltsfoot ketone for effectively preventing or treating liver steatosis or fatty liver. In addition, coltsfoot ketone is taken as a natural small molecular compound, has obvious effect of relieving lipid accumulation induced by high-fat diet, plays an important role in the treatment of non-alcoholic fatty liver disease, and has wide application prospect.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, and alternatives falling within the spirit and principles of the invention.
Claims (8)
1. The coltsfoot ketone is applied to preparing medicines for preventing and treating hepatic steatosis or fatty liver.
2. The use of coltsfoot ketone according to claim 1 in the preparation of a medicament for preventing and treating hepatic steatosis or fatty liver, characterized in that: the prevention and treatment include prevention, alleviation and treatment.
3. The use of coltsfoot ketone according to claim 1 in the preparation of a medicament for preventing and treating hepatic steatosis or fatty liver, characterized in that: the fatty liver is nonalcoholic fatty liver.
4. The use of coltsfoot ketone according to claim 1 in the preparation of a medicament for preventing and treating hepatic steatosis or fatty liver, characterized in that: the prepared medicine for preventing and treating liver steatosis or fatty liver is an oral preparation medicine.
5. The use of coltsfoot ketone according to claim 4 for preparing a medicament for preventing and treating hepatic steatosis or fatty liver, wherein the coltsfoot ketone comprises: the oral preparation medicine is one of capsule preparation, soft capsule preparation, oral liquid preparation, dripping pill preparation or tablet preparation medicine.
6. The use of coltsfoot ketone according to claim 4 for preparing a medicament for preventing and treating hepatic steatosis or fatty liver, wherein the coltsfoot ketone comprises: the oral preparation also contains pharmaceutically acceptable auxiliary materials and/or carriers.
7. The use of coltsfoot ketone according to claim 1 in the preparation of a medicament for preventing and treating hepatic steatosis or fatty liver, characterized in that: the dosage of coltsfoot ketone is 15mg/kg-30mg/kg.
8. The use of coltsfoot ketone according to claim 1 in the preparation of a medicament for preventing and treating hepatic steatosis or fatty liver, characterized in that: the dosage of coltsfoot ketone is 15mg/kg and 30mg/kg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310044103.7A CN115998726B (en) | 2023-01-29 | 2023-01-29 | Application of coltsfoot ketone in preparing medicament for preventing and treating liver steatosis or fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310044103.7A CN115998726B (en) | 2023-01-29 | 2023-01-29 | Application of coltsfoot ketone in preparing medicament for preventing and treating liver steatosis or fatty liver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115998726A true CN115998726A (en) | 2023-04-25 |
| CN115998726B CN115998726B (en) | 2024-04-30 |
Family
ID=86021186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310044103.7A Active CN115998726B (en) | 2023-01-29 | 2023-01-29 | Application of coltsfoot ketone in preparing medicament for preventing and treating liver steatosis or fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115998726B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497476A (en) * | 2016-02-17 | 2016-04-20 | 王景明 | Traditional Chinese medicine for treating fatty liver |
-
2023
- 2023-01-29 CN CN202310044103.7A patent/CN115998726B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497476A (en) * | 2016-02-17 | 2016-04-20 | 王景明 | Traditional Chinese medicine for treating fatty liver |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115998726B (en) | 2024-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baradaran Rahimi et al. | Antiinflammatory and anti‐cancer activities of pomegranate and its constituent, ellagic acid: Evidence from cellular, animal, and clinical studies | |
| KR101809172B1 (en) | Composition for preventing, improving or treating metabolic disease comprising Akkermansia muciniphila strain or its culture broth cultivated in medium without mucin as effective component | |
| Jang et al. | Anti-inflammatory effects of an ethanolic extract of guava (Psidium guajava L.) leaves in vitro and in vivo | |
| KR20080105470A (en) | Food composition containing ginseng fruit extract for preventing and improving obesity | |
| US20150306165A1 (en) | Plant extract composition for inhibiting adipocytes, reducing body fat, promoting weight loss and increasing lipid metabolism as well as application thereof | |
| CN102630161A (en) | Method of slowing the aging process by activating Sirtuin enzymes with a combination of fucoxanthin and punicic acid | |
| Xianchu et al. | Grape seed proanthocyanidin extract supplementation affects exhaustive exercise-induced fatigue in mice | |
| EP2859896A1 (en) | Pharmaceutical compositions for the treatment of muscular disorders | |
| Han et al. | Gentisic acid prevents diet-induced obesity in mice by accelerating the thermogenesis of brown adipose tissue | |
| KR101018531B1 (en) | Composition for preventing or treating obesity or metabolic syndrome comprising polygonatum falcatum or polygonatum sibiricum extract as an active ingredient | |
| CN115998726B (en) | Application of coltsfoot ketone in preparing medicament for preventing and treating liver steatosis or fatty liver | |
| Sutirta-Yasa et al. | Antioxidant potential and hypolipidemic effects of combined purple sweet potato (Ipomoea batatas L.) tuber extract with honey in rats given high cholesterol feed | |
| EP3766363A1 (en) | Composition for improving skin conditions | |
| KR20100088007A (en) | A composition for preventing or treating of fatty liver comprising an extract of chestnut inner shell | |
| WO2022089591A1 (en) | Application of glucosamine in preparation of non-alcoholic fatty treatment drugs | |
| CN109172633A (en) | A kind of Radix Gentianae Macrophyllae extract and the preparation method and application thereof | |
| KR101050003B1 (en) | Composition for inhibiting obesity, containing the extract as an active ingredient | |
| CN115944640B (en) | Application of stemonine in preparing medicine for treating non-alcoholic fatty liver | |
| Boncheva et al. | Administration of bioflavonoides improves plasma levels of adipocyte hormones | |
| Uddin et al. | Inhibitory effects of chung hun wha dam tang (CHWDT) on high-fat diet-induced obesity via AMP-activated protein kinase activation | |
| CN112121056A (en) | Application of composition of small-molecule fucoidin and fucoxanthin in preparation of composition for improving non-alcoholic fatty liver disease | |
| WO2023223943A1 (en) | Vascular endothelium function-improving composition | |
| KR20150136668A (en) | Composition for antidiabetic or antiobesity activity comprising sprout extract as effective component | |
| KR20140104090A (en) | A pharmaceutical composition for treating and preventing fatty liver diseases containing curcumin as an active ingredient | |
| CN117298128A (en) | Application of arbutin in preparation of medicine for preventing and treating obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |